AbbVie Reports Results of Depatux-M (depatuxizumab mafodotin) in P-III INTELLANCE-1 Study for Glioblastoma
Shots:
- The P-III study results involves assessing of Depatux-M (depatuxizumab mafodotin- ABT-414) + SOC therapy of radiation + temozolomide vs PBO + SOC in 639 patients with newly diagnosed EGFR-amplified GBM
- AbbVie has halted the enrollment of patients in all ongoing studies of Depatux-M due to its inability to meet 1EP- demonstrated no survival benefits & no new safety is observed. IMDC has also recommended for the termination of INTELLANCE-1 study due to lack of survival benefits
- Depatux-M (depatuxizumab mafodotin) is an ADC targeting EGFR-amplification- evaluated to treat glioblastoma under the collaboration of AbbVie & RTOG foundation
Ref: AbbVie | Image:AbbVie
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com